Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
The BTK inhibitor ibrutinib is used to treat chronic lymphocytic leukaemia, however some patients develop resistance to the drug. Here, the authors use genomic analyses to examine the clonal evolution of 5 patients that develop resistance to ibrutinib.
Main Authors: | Jan A. Burger, Dan A. Landau, Amaro Taylor-Weiner, Ivana Bozic, Huidan Zhang, Kristopher Sarosiek, Lili Wang, Chip Stewart, Jean Fan, Julia Hoellenriegel, Mariela Sivina, Adrian M. Dubuc, Cameron Fraser, Yulong Han, Shuqiang Li, Kenneth J. Livak, Lihua Zou, Youzhong Wan, Sergej Konoplev, Carrie Sougnez, Jennifer R. Brown, Lynne V. Abruzzo, Scott L. Carter, Michael J. Keating, Matthew S. Davids, William G. Wierda, Kristian Cibulskis, Thorsten Zenz, Lillian Werner, Paola Dal Cin, Peter Kharchencko, Donna Neuberg, Hagop Kantarjian, Eric Lander, Stacey Gabriel, Susan O’Brien, Anthony Letai, David A. Weitz, Martin A. Nowak, Gad Getz, Catherine J. Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2016-05-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/ncomms11589 |
Similar Items
-
Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
by: Lauren E. Kueffer, et al.
Published: (2021-06-01) -
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
by: Raji E Joseph, et al.
Published: (2020-11-01) -
Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2021-02-01) -
Btk regulates macrophage polarization in response to lipopolysaccharide.
by: Joan Ní Gabhann, et al.
Published: (2014-01-01) -
Molecular investigations of BtK and WASP
by: MacCarthy-Morrogh, Lucy
Published: (1998)